

# Aparna R Parikh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4907047/publications.pdf>

Version: 2024-02-01

70  
papers

3,705  
citations

361296

20  
h-index

149623

56  
g-index

74  
all docs

74  
docs citations

74  
times ranked

5485  
citing authors

#	ARTICLE	IF	CITATIONS
1	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359.	2.3	758
2	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	15.2	359
3	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	3.4	353
4	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 806-815.	2.3	310
5	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	7.7	243
6	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Annals of Surgery, 2019, 269, 733-740.	2.1	235
7	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	3.2	178
8	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nature Cancer, 2021, 2, 1124-1135.	5.7	112
9	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1109-1133.	2.3	92
10	Concurrent therapy with immune checkpoint inhibitors and TNF $\alpha$ blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89
11	Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4814-4822.	3.2	82
12	Response to Anti-EGFR Therapy in Patients with BRAF non-V600E Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	3.2	79
13	Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. Journal of Clinical Oncology, 2022, 40, 2846-2857.	0.8	77
14	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist, 2019, 24, 1340-1347.	1.9	73
15	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	3.2	67
16	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	7.7	61
17	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 2988-2995.	3.2	42
18	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. Journal of the American College of Surgeons, 2020, 230, 912-924.	0.2	42

#	ARTICLE	IF	CITATIONS
19	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE <sub>2</sub> -receptor E-type 4 (EP4), in patients with advanced cancers. , 2020, 8, e000222.		34
20	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 123-132.	1.5	30
21	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discovery, 2022, 12, 1462-1481.	7.7	30
22	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 4027-4034.	0.7	21
23	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	1.3	21
24	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 90-95.	0.4	20
25	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. Oncologist, 2019, 24, e275-e283.	1.9	18
26	Medical Oncologists'™ Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. Journal of Oncology Practice, 2017, 13, e185-e196.	2.5	17
27	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421.	1.1	17
28	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	1.9	16
29	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	1.5	16
30	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2017, 21, 1831-1840.	0.9	14
31	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology, 2021, 21, 1119-1126.	0.5	13
32	POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. Oncologist, 2019, 24, 1557-1561.	1.9	12
33	Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. Oncologist, 2020, 25, 1015-1022.	1.9	11
34	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. Current Treatment Options in Oncology, 2021, 22, 100.	1.3	11
35	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
36	Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience. Oncologist, 2021, 26, e1581-e1588.	1.9	10

#	ARTICLE	IF	CITATIONS
37	Fast-TRKing Drug Development for Rare Molecular Targets. <i>Cancer Discovery</i> , 2017, 7, 934-936.	7.7	9
38	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1846-e1855.	1.4	9
39	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2859-2870.	0.9	8
40	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	3.2	8
41	A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 391-391.	0.8	8
42	Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with <i>KRAS</i> Wild-type Metastatic Colorectal Cancer: A Meta-analysis. <i>Oncologist</i> , 2022, 27, 371-379.	1.9	8
43	Methylated Septin9 ( <i>mSEPT9</i> ): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 90-98.	0.7	8
44	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	2.0	7
45	Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon. <i>Modern Pathology</i> , 2022, 35, 1723-1731.	2.9	7
46	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	1.9	6
47	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	2.1	6
48	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1587-e1593.	1.4	6
49	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in <i>KRAS</i> wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	1.6	5
50	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
51	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 242-252.	0.7	4
52	fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	4
53	ReCAP: Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 259-260.	2.5	3
54	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2856-2865.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.. Journal of Clinical Oncology, 2018, 36, 49-49.	0.8	3
56	Outcomes following liver SBRT for metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 418-418.	0.8	2
57	Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 659-659.	0.8	2
58	Gender, Productivity, and Philanthropic Fundraising in Academic Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1401-1406.	2.3	2
59	The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. JCO Global Oncology, 2020, 6, 13-13.	0.8	1
60	Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF. , 2021, , .		1
61	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. British Journal of Cancer, 2021, , .	2.9	1
62	HER2 positivity in brain metastases from gastrointestinal primary malignancies.. Journal of Clinical Oncology, 2018, 36, 61-61.	0.8	1
63	The immune milieu of anal squamous cell carcinoma and implications of IDO expression on outcome.. Journal of Clinical Oncology, 2018, 36, 659-659.	0.8	1
64	Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs). Cancer Research, 2022, 82, CT134-CT134.	0.4	1
65	The Unintentional Perpetuation of the Gender Divide. Journal of General Internal Medicine, 2020, 35, 910-912.	1.3	0
66	ASCO Voices 2020. Journal of Clinical Oncology, 2020, 38, 3231-3232.	0.8	0
67	The Use of Single-Agent Versus Multiple-Agent Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
68	ASO Visual Abstract:ÂNeoadjuvant versusÂPostoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2021, 28, 690-691.	0.7	0
69	EPR22-117: Evaluation of the Influence of the BRAF V600E Mutation and of the Microsatellite Instability on the Overall Survival (OS) of Metastatic CRC Patients Based on Real World Data. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, EPR22-117.	2.3	0
70	Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, , .	0.9	0